Market Intelligence, Clinical Progress, and High-Purity Reagents for Eosinophilic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for RNASE3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RNASE3 Native Recombinant Protein / ECD-Fc Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293-expressed, native glycosylation and preserved ribonuclease activity. |
View RNASE3 Products |
| Gene Delivery | RNASE3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Secretion-competent expression cassette. |
View RNASE3 Products |
| Benchmark Ab | Anti-RNASE3 Recombinant Antibody High-affinity positive control for ELISA, Western Blot, and neutralization assays. |
View RNASE3 Products |
| Validator | RNASE3 siRNA Set For specific knockdown verification and specificity controls in eosinophil and epithelial models. |
View RNASE3 Products |
| Related Target: RNASE2 | Eosinophil-Derived Neurotoxin (EDN) Homolog counter-screening and dual eosinophil granule biology. |
View RNASE2 Products |
| Related Target: IL5 | Interleukin-5 Upstream cytokine driving eosinophil activation, survival, and RNASE3 release. |
View IL5 Products |
| Related Target: EPX | Eosinophil Peroxidase Companion toxic granule protein; co-release biomarker for oxidative tissue damage. |
View EPX Products |
| Related Target: IL5RA | IL-5 Receptor Alpha Upstream eosinophil activation pathway; synergy with RNASE3 effector biology. |
View IL5RA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| RNase Family Selectivity (RNASE1/2/3 cross-reactivity) | Human RNASE1, RNASE2, RNASE3 ortholog proteins available with >95% purity; strict mass spec verification for off-target screening. |
| Enzymatic Activity Preservation | Native folding confirmed (disulfide bonds); Endotoxin controlled (<1EU/ug) to prevent false inhibition signals. |
| Neutralizing Antibody Screening | High-concentration protein formulation (mg/mL) for SPR and BLI binding assays. |
| Glycosaminoglycan (GAG) Binding Validation | Sequence-verified heparin-binding domain preservation; suitable for affinity chromatography and cytotoxicity assays. |
| Catalytic vs. Non-Catalytic Mechanism Discrimination | WT and catalytic-dead mutant recombinant proteins available as enzymatic negative controls. |
| Species Translation (Human to Cyno/Mouse) | Human / Cynomolgus / Mouse RNASE3 recombinant proteins, >95% purity, endotoxin controlled. |
Live RNASE3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RNASE3 (Eosinophil Cationic Protein, ECP) therapeutics and diagnostics is intensifying, with major players shifting focus from broad immunosuppressants and upstream cytokine blockers to targeted modulation of direct effector molecules. As anti-IL-5 and anti-IL-5R therapies dominate current markets, the next wave of R&D is targeting downstream granule proteins—particularly RNASE3—to address residual tissue damage and refractory eosinophilic inflammation while preserving antimicrobial defenses. RNASE3 serves both as a clinical biomarker for asthma severity and as a cytotoxic agent driving tissue remodeling in eosinophilic esophagitis (EoE), chronic rhinosinusitis with nasal polyps (CRSwNP), and hypereosinophilic syndrome (HES). Emerging modalities now focus on selective RNASE3 enzymatic inhibitors, neutralizing antibodies, and GAG-binding inhibitors to block cytotoxicity without complete eosinophil depletion. The convergence of biomarker quantification and therapeutic intervention creates a strong demand for high-purity recombinant proteins with native post-translational modifications, which TarMart delivers through its HEK293 expression platform.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Early Biotech | Eosinophilic Esophagitis (EoE), Asthma | Enzymatic Activity Assay (Need high-purity active RNASE3 with preserved RNase activity and catalytic-dead controls) |
| Neutralizing Antibodies | BioVentures, Emerging Biotech | Hypereosinophilic Syndrome (HES), Severe Asthma, Atopic Dermatitis | Epitope Mapping & Selectivity Assay (Need RNASE1/2/3 homolog panel for cross-reactivity screening) |
| Biomarker Diagnostics | Diagnostic Companies | Severe Eosinophilic Asthma, Eosinophilic Esophagitis (EoE) | Quantitative ELISA Standards (Need calibrated recombinant RNASE3 protein, endotoxin controlled) |
| Upstream Biologics (Anti-IL5/Siglec-8) | GSK, AstraZeneca, Allakos, Sanofi | Severe Asthma, EoE, HES | Pharmacodynamic Markers (RNASE3 level monitoring in vitro for target engagement) |